



REVIEW ARTICLE

REVIEW ON CELLULAR SIGNALING, GROWTH FACTORS, AND MECHANICAL STIMULUS IN NERVE REGENERATION

Ezegbe Chekwube Andrew^{1,3*} , Amarachi Grace Ezegbe² 

¹Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria.

²Department of Home Science and Management, University of Nigeria, Nsukka, Nigeria.

³Nanoscience and Advanced Materials, Graduate Program (PPG-Nano), Federal University of ABC, Avenida dos Estados, Santo Andre, Sao Paulo, Brazil.

Article Info:



Article History:

Received: 14 September 2024

Reviewed: 18 November 2024

Accepted: 23 December 2024

Published: 15 January 2025

Cite this article:

Ezegbe CA, Ezegbe GA. Review on cellular signaling, growth factors, and mechanical stimulus in nerve regeneration. Universal Journal of Pharmaceutical Research 2024; 9(6): 77-83. <http://doi.org/10.22270/ujpr.v9i6.1246>

*Address for Correspondence:

Ezegbe Chekwube Andrew, Department of Pharmaceutical Technology and Industrial Pharmacy, University of Nigeria, Nsukka, Nigeria. Tel: +2348038042802; E-mail: ezegbe.chekwube@unn.edu.ng

Abstract

The nervous system consists of the autonomous and peripheral. Injury on the peripheral nerve which occurs due to trauma, accident and other associated factors always results in a huge loss of both the motor and sensory functions. The injured nerves can be successfully restored although it requires a lot of molecular response in order to rebuild the functional axons. When this is achieved, the damaged nerve can accurately connect with their original targets. The complete recovery of PNI has not been optimized. Exogenous growth factors (GFs) are a new therapeutic strategy that can be used in nerve regeneration. The mechanism of action of growth factor is based on the ability to activate the signaling cascades via binding to the individual receptors in order to exert the multiple effects and restore the neuron and tissue regeneration. Although the GFs are limited by their short half-life and rapid deactivation. The use of nerve conduits has been able to reduce these limitations. The nerve conduits have been good biocompatibility and biofunctionality properties.

Keywords: Axons, growth factors, peripheral nerve injury, signaling cascade.

INTRODUCTION

Cellular signaling can be defined as perturbations of cellular homeostasis which causes cells to respond to different types of stimuli which could be in form of mechanical (mechanotransduction), electrical (electrotransduction) and chemical (chemotransduction) [1]. Cell signaling is a process that enables a cell to interact with itself, other surrounding cells and the host environment [1]. Three major components are involved in cell signaling. They include the: signal, receptor and effector [2]. Signaling could occur in different forms viz endocrine (long range communication), paracrine (short range), juxtacrine (contact-dependent signaling) and autocrine. Growth factors are defined as a set of cell-produced proteins and polypeptides which have the ability to regulate cellular proliferation and differentiation [3]. Growth factors that are soluble in nature can easily be incorporated directly into nerve conduits. They play a crucial role in supporting the numerous cell types that are involved in cell regeneration [4]. Examples of growth factors commonly used in nerve regeneration include [5]:

- Nerve growth factors (NGFs)
- Glial cell line-derived neurotrophic factor (GDNF)
- Ciliary neurotrophic factor (CNTF)
- Vascular endothelial growth factor (VEGF)
- Neurotrophin -3 (NT-3)
- Leukemia inhibitory factor (LIF)
- Growth associated factor (GAP-43)
- Neurotrophin -4 (NT-4)
- Fibroblast growth factor (FGF)
- Platelet derived growth factor (PDGF)

Nerve growth factor (NGF): NGF was the first neurotrophic factor to be identified. It consists of three subunits: γ , β and α . Its main function is in the maintenance of basal forebrain cholinergic neurons, sympathetic neurons and nociceptive sensory neurons [6]. The mechanism of action is based on its ability to bind to tyrosine kinase receptor (trkA) which promotes the choline acetyltransferase expression and its effect on neuron differentiation and maintenance [7]. Nerve growth factors can be increased at the site of injury by insertion of Schwann cells into the nerve scaffolds [6]. The neurotrophic factor consists of structurally and

functionally peptides that are related and they mediate potent survival and differentiation effects, both in central and peripheral nervous system [7]. Neurotrophins exist as noncovalent homodimers that are biologically active in nature [8, 9]. Each molecule of the homodimer is made up of two pairs of antiparallel beta strands. Each of these beta strands is made up of highly flexible short loops [10]. The uniqueness of neurotrophins is in their ability to bind to two classes of receptors which include the tropomyosin receptor kinase (TRK) and the tumor necrosis factor (TNF) alpha family of P₇₅ receptor. The P45 receptor has similar affinity whenever it binds to neurotrophins, while the tropomyosin receptor kinase are more specific in their binding. Nerve growth factors bind to trkA and BDNF, while NT-4/5 subsequently binds to trkB [11].

Neurotrophic cytokines: They belong to the family of pleiotropic glycoprotein molecules which play a major role in biological activities, induction of immune and inflammatory responses, regulation of hematopoiesis, control of cellular proliferation/differentiation and wound healing induction [12]. The main signal mechanism for neurotrophic cytokine family is carried out through recruiting the common signal transduction receptor subunit [13, 14]. Gp130 is not directly activated by neurotrophic cytokines, but they bind to specific ligand-binding subunits. IL-6 binds to the IL-6 receptor, LIF binds to the LIF receptor (LIFR) and the CNTF binds to the CNTF receptor (CNTFR).

Brain derived neurotrophic factor (BDNF): They are found majorly in the brain and periphery. Their major functions are in the promotion of the neuronal and synaptic growth, maintenance of existing neurons in the cortex and basal forebrain. Its mechanism of action is similar to that of NGF where they bind to the trkB receptor and form the BDNF-trkB complex [14].

The role of growth factors in nerve regeneration

The neurotrophic growth factors belong to the peptide family. Their basic role is to ensure the survival and differentiation of nerve fibers in both the central and peripheral nervous system [15, 16].

Neurotrophins are molecules that are made up of non-covalent homodimer beta chains [17]. They are separated from each other due to the composition of the binding sites. They play a major role in neurotrophic factors because they help to guide the axons in growth cone during regeneration [18].

Glial cell-line derived neurotrophic factor (GDNF)
The GDNF family consist of GDNF, persephin (PSP), neurturin (NTN) and artemin (ART). The prominent member, GDNF helps in the survival of motor neurons, while NTN assists in the survival of sympathetic neurons [19]. They belong to the growth factor-β family of neurotrophic factors. There are two major parts of receptors associated with GDNF. They are the GFRα1 subunit and C-ret subunit. The former serves as the binding site, while the later participates in signaling [20].

Ciliary neurotrophic factor (CNTF)

It belongs to the family of interleukin-6. It is during an injury that the production of CNTF increases. The ligand binding of CNTF to the CNTF receptor-α (CNTFR) subunit triggers signals via the Janus kinase-

signal transducers and activators of transcription pathway via the formation of a complex with the subunits of glycoprotein-130 [21, 22].

Interactions between neurotrophic factors

There are differences that exist for both GDNF family and neurotrophic cytokines in terms of receptor systems and related signal transduction pathways [23]. The neurotrophins and GDNF family are homodimeric and biologically active molecules, while neurotrophic cytokines are long chain α-helix bundle proteins [24, 25]. Damage to the axon leads to significant increase of BDNF mRNA within 8 hours [26], while in a healthy neuron, BDNF is under expressed, thus within the 7th day of injury, the BDNF level returns to normal. Following external damage, trkB mRNA increases on the second day, while on the 7th day, it reaches the peak. The content and localization of the axonal damage are two major factors that affect the neurotrophic cytokine receptors [27]. After damage to the axon, cellular and molecular changes occur, and they are characterized by phagocytic processes [28]. Whenever an injury occurs at the axonal end, the expression of nerve growth factor (NGF) and brain derived neurotrophic factor (BDNF) increases in the distal part, while the expression of NT-3 and NT-4 neurotrophin reduces [29]. In an intact nerve, the level of NGF mRNA is very low, while in a damaged axon, it increases to 10 times in the distal part within the first 12 hours. After 72 hours post-injury, it decreases back to its normal level and remains like that for about three weeks [30-35]. In a damaged axon, the BDNF mRNA increases at the distal part, although the increase is slow when compared to that of NGF mRNA. Although GDNF has been detected in healthy nerve, in a damaged axon, it usually peaks in distal part after 7th day and remains like that for atleast two weeks [36].

Mechanical stimulus (mechanisms, biomaterials, types of stimulus and results)

Ultrasound: Ultrasound can serve two major functions: as a diagnostic and as a therapeutic tool. Ultrasound waves are known to generate mechanical energy which stimulates tissue regeneration [37]. The ultrasound wave can come in either continuous or pulsed. The low intensity pulsed ultrasound is preferable due to the fact that it involves low intensity of mechanical wave in a pulsatile manner, which results in reduction of heat generation [38]. The ultrasound stimulation that regulates intracellular signaling mechanism induction of fibroblasts by mechanical force leads to enhancement of collagen production and also provision of a structural support for axonal repair [38].

Extracorporeal shock wave (ESW)

The difference between extracorporeal shock wave (ESW) and ultrasound is that ESW applies a higher mechanical pressure that is about one thousand (1,000) times compared to that of ultrasound [39]. ESW has a lot of therapeutic applications, among them is in the repair of peripheral nerve injury.

Types of extracorporeal shock wave

- a. Focused extracorporeal shock wave (FESW)
- b. Radial extracorporeal shock wave (RESW)

Focused extracorporeal shock wave is applied in deep treatment areas that can reach up to 12 cm, while radial extracorporeal shock wave is applied to a depth of about 3-4 cm [40]. Extracorporeal shock wave generates a mechanical stimulus that provokes two major physical effects which include mechanotransduction and cavitation. In peripheral nerve repair, mechanotransduction plays a major role by affecting the development of myelin gene regulation, Schwann cell differentiation and axonal regeneration [41].

Biomaterials for Peripheral Nerve Injury repair.

In tissue engineering, any biomaterial used in nerve conduit production must possess some basic characteristics properties which include: biocompatibility, biodegradability, permeability, biochemical properties, flexibility and resistance to collapse and tension [42]. The biocompatibility property of a biomaterial is further subdivided into 3 [43, 44]:

- a. **Blood compatibility:** This talks about the ability of the biomaterial not to initiate hemolysis or coagulation in the human body
- b. **Histocompatibility:** The biomaterial should not be able to induce side effects on the surrounding tissues.
- c. **Mechanical compatibility:** The mechanical properties presented by the biomaterial must be similar to that of the host tissue.

Permeability is another important parameter that should be possessed by a conduit biomaterial. This is because it enhances cell viability and also promotes the exchange of gas, nutrients and waste materials [45]. According to Funakoshi *et al*; conduit permeability increases with pore size. Thus to facilitate nerve growth and repair, nerve conduits with large pores are preferable. In nerve regeneration, a semi-permeable conduit is more preferable when compared to both low permeable and impermeable conduits [46]. The nerve guide diameter has a lot of influence on the nerve regeneration outcome. This is because the proximal and distal stumps of the injured nerve has to match the nerve guide diameter [47]. The conduit wall thickness also has a major role to play in axonal growth. According to Naveilhan *et al*; conduit walls that are more than 0.8 mm thick reduces axonal growth which affects the permeability and porosity reduction which are important factors to consider in nerve regeneration [47]. An idea conduit should be easy to suture, and it should be flexible enough to allow the needle to pass via the wall without the escape of the nerve stumps from the conduit lumen [48].

Natural based biomaterials

In nerve regeneration, a lot of natural-based biomaterials has been used. They include polysaccharides such as: hyaluronic acid, alginate, chitin and chitosan. Proteins such as: collagen, gelatin, silk fibroin, fibrin and keratin [49].

Polysaccharides

1. Hyaluronic acid (HA): It is composed of glycosaminoglycan moiety which is involved in regulation of different cellular processes [50]. Some unique properties associated with hyaluronic acid include: biocompatibility, support of axonal growth

and its non-adhesive nature [51]. Although some of the limitations associated with HA which are: fast degradation and low mechanical properties, it can still be used as a conduit internal filler mostly in hydrogel form.

2. Alginate: Alginate has a wild application in the biomedical field [52]. Chemical reactions is one major way that is used in the modification of alginate. When alginate is oxidized with sodium alginate, it gives rise to alginate dialdehyde [53]. One of the limitations associated with alginate use in promoting nerve regeneration is its weak mechanical resistance, thus it is advisable to use alginate in combination with other polymers in order for it to withstand the physiological loading conditions [54]. According to Pfister *et al*; he blended alginate with a biomaterial of natural origin-chitosan which gave rise to a support of nerve regeneration for short nerve gaps. Due to the hydrophilic nature of the chitosan, the blended mixture possessed a good permeability and adequate mechanical strength [55]. The techniques used in the manufacture of alginate include: magnetic templating, electrospinning, gas forming, emulsion freeze drying and 3D printing [56, 57]. Alginate can also be used in nerve regeneration as a conduit internal filler for growth factor delivery [58].

3. Chitin and chitosan: Chitin is a member of the glycosaminoglycan family with the presence of N-acetyl-D-glucosamine moiety. The most abundant polysaccharide in nature is cellulose, followed by chitin. Its most abundant in nature is found in the exoskeleton of arthropods [59]. Chitin has a wide range of applications in the food industry, agriculture, pharmaceuticals and medicine especially when used in its partial deacetylated form as chitosan [60, 61]. They include its biocompatibility, ability to support axonal growth and tendency to reducing scar [62]. Although chitosan has low mechanical strength, it can be modified in order to improve its mechanical stability [63]. Other unique properties associated with chitosan include: its versatility and easy modification of the surface structure [64]. A study investigated nerve regeneration in rat sciatic nerves 3 months after 10 mm nerve repair with chitosan conduits that had three different deacetylation degrees [65]. At the end of the study, there was no significant differences among the experimental groups at functional, biomolecular and morphological levels [66]. Reaxon® a chitosan nerve conduit was commercialized in 2015. It was able to bridge nerve gaps up to 26 mm due to some of its unique advantages such as transparency, flexibility and resistance to collapse [67].

Proteins

Collagen: Collagen is the most abundant protein in the human body, thus one of the main reasons it has been used over the years in nerve conduit repair [73]. According to Saltzman *et al*; 10 mm long hollow conduits reported better results in rat nerve regeneration and muscle re-innervation when compared to collagen polyglycolic acid (PGA) filled conduits. The limitations associated with the use of collagenase in nerve tissue repair is due to its low resistance to mechanical stress and weak manipulability [74].

Table 1: Relevant studies on chitosan based conduits.

Method of conduit production	<i>In vitro</i> analysis	Results	References
Extrusion process, washing and hydrolysis	A short and long term analysis on the 10 mm rat sciatic nerve gap.	No <i>in vivo</i> toxicity. Short term: Higher number of activated Schwann cells in the distal segments of nerves.	[68]
Extrusion process	A 10 mm rat sciatic nerve gap that was repaired for 3 months	No conduit detachment or collapse from the ultrasonography results.	[69]
Extrusion process, washing and hydrolysis	A short and long term analysis on the 15 mm rat sciatic nerve gap, muscle weight assessment	Higher muscle reinnervation in rats repaired with autograph in comparison with chitosan group. A larger and higher number of myelinated fibers was observed in the autograft in comparison to chitosan experimental group.	[70]
Freeze-cast process	A 12 weeks repair on a 10 mm sciatic nerve gap with a porous chitosan conduit	Observational of an axonal outgrowth across the conduit	[71]
Mold-mandrel processing	Characterization of morphological and mechanical properties of chitosan conduit. Repair of 12 mm rat sciatic nerve gap with cell enriched chitosan conduit for 3 months	After 3 months, the conduit became thinner although there was wall and lumen integrity.	[72]

It is recommended that collagen should be blended with other biomaterials like chitosan in order to increase its mechanical strength [75].

Gelatin: The thermal denaturation of collagen results in the production of gelatin. The mechanical and physical properties of gelatin could be easily altered by using various cross-linking agents [76]. One of the most common cross-linkers used was genipin, a natural substance with low cytotoxicity. According to Chen Y *et al.*, he used a genipin cross-linked gelatin conduit to repair a 10 mm rat sciatic nerve for 8 weeks. The result obtained after 8 weeks, showed that most of the regenerated axons were not myelinated [76]. Proanthocyanidin was another cross linker that was used to stabilize a gelatin conduit. According to Liu *et al.*; it was used to repair a 10 mm nerve gap and the regeneration was assessed 8 weeks after the repair. The *in vivo* studies after 8 weeks showed that the conduit was well integrated into the surrounding tissues [77]. Another natural cross linker used was bisvinylsulfomethyl. The result obtained after 8 weeks in a 10 mm rat sciatic nerve defect showed that it reduced gelatin swelling and improved its mechanical properties [78].

Silk fibroin

Silk fibroin is used in biomedical applications due to some unique characteristics that it possesses. It contains repeated amino acidic sequence, thus having a very good mechanical properties. It is also easily degradable [82]. Mature silk has been shown to possess good tensile and mechanical properties to conduits, when compared to conduits produced with only fibroin solution. The silk fibrin could easily be blended using different biomaterials to reach the target mechanical strength [83].

Fibrin

It is used in scaffold tissue engineering due to its unique properties which include high biocompatibility, versatility, high dissolving and coagulating properties which can be modified [84, 85]. According to Kalbarmathen *et al.*; he demonstrated the effect in rat sciatic nerve regeneration of a conduit that was made by fibrin glue to repair 10 mm defects. The result obtained indicated that the fibrin glue demonstrated a better axon regeneration length in comparison PHB conduits 2 weeks after the repair [85].

Table 2: Relevant studies on protein based conduits.

Mode of conduit production	Analysis	Results	References
Genepin cross-linked gelatin solution poured into a mandrel	A non-porous and porous genepin cross-linked gelatin conduit were compared and used to repair a 10 mm rat sciatic nerve. Microscopic observation and characterization of the conduit	A faster degradation and lower mechanical strength was recorded in the porous gelatin conduit. There was a significant higher nerve conductive velocity in rats that were repaired with the porous conduit	[79]
Proanthocyanidin cross-linked gelatin solution	<i>In-vitro</i> enzymatic degradation and biocompatibility assay. A 10 mm rat sciatic nerve defect was used to repair the proanthocyanidin cross-linked gelatin conduit for 8 weeks	Conduit has resistance to degradation by digestive enzymes. Schwann cell adhesion and growth was supported by gelatin and proanthocyanidin release	[80]
Photo fabrication of the gelatin conduit	10 mm rat sciatic nerve gap was repaired with gelatin conduit for 12 months	At 12 weeks, the gelatin conduit was degraded and absorbed with no signs of any inflammatory reactions	[81]

Keratin

It has some unique characteristics that makes it useful as a biomaterial. They include its biocompatibility, biodegradability, bioactivity and its hydrophilic surface. Although it has some limitations such as poor physical and mechanical properties, it can be improved by using various cross-linking agents [86]. When keratin is used as a hydrogel-filler for conduits in mice, it has proven to be effective in promoting nerve regeneration in short gaps of 5-15 mm [87]. Gupta and Najak used keratin as a protein source for scaffold fabrication. The results obtained showed that they produced a keratin-alginate scaffold [88].

Polyesters

A polyester is a biopolymer that is naturally biodegradable. The most commonly used type in tissue engineering is polyhydroxyalkanoates (PHA). Some advantages associated with PHA include pH stability and biocompatibility. One of the limitations of its use is high cost, although it could be reduced to the barest minimum by the development of recombinant microorganisms [89].

CONCLUSIONS

Overtime, there has been an advancement on the comprehension of peripherous nervous injury, although there is still room for improvement. With growing research on other growth factors, they hold a great promise as a tool for studying intracellular communication among cells.

ACKNOWLEDGEMENT

Authors are thankful for University of Nigeria, Nsukka, Nigeria to provide necessary facilities for this work.

AUTHOR'S CONTRIBUTION

Ezegbe CA: investigation, visualization, writing editing. **Ezegbe AG:** review, editing. Both authors checked and approved final version of the manuscript.

DATA AVAILABILITY

The accompanying author can provide the empirical data that were utilized to support the study's conclusions upon request.

CONFLICT OF INTEREST

None to declare.

REFERENCES

- Benoit JP, Faisant N, Venier-Julienne MC, and Menei P (2000). Development of microspheres for neurological disorders: From basics to clinical applications. *Journal of Controlled Release* 65: 285–296.
- Arathi N, Prashant C, Bhasker S, Katharina F (2019). Review on conceptual evolution of cell signaling. *International Journal of Molecular Science*. 20, 3292; 1-44.
- Boyd JG and Gordon T (2003a) Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury. *Molecular Neurobiology* 27: 277–324.
- Boyd JG and Gordon T (2003b) Glial cell line-derived neurotrophic factor and brain-derived neurotrophic factor sustain the axonal regeneration of chronically axotomized motoneurons *In vivo*. *Experimental Neurology* 183: 610–619.5
- Engler AJ, Sen S, Sweeney HL, and Discher DE (2006) Matrix elasticity directs stem cell lineage specification. *Cell* 126: 677–689.
- Espinosa-Jeffrey A, Oregel K, Wiggins L, et al. (2012) Strategies for endogenous spinal cord repair: HEMA hydrogel to recruit migrating endogenous stem cells. *Advances in Experimental Medicine and Biology* 760: 25–52.
- Evans GR (2001). Peripheral nerve injury: A review and approach to tissue engineered constructs. *The Anatomical Record* 263: 396–404.
- Fernandez L, Komatsu DE, Gurevich M, and Hurst LC (2018). Emerging strategies on adjuvant therapies for nerve recovery. *The Journal of Hand Surgery American Society for Surgery of the Hand* 43: 368–373.
- Fournier E, Passirani C, Montero-Menei CN, and Benoit JP (2003). Biocompatibility of implantable synthetic polymeric drug carriers: Focus on brain biocompatibility. *Biomaterials* 24: 3311–3331.
- Fu SY and Gordon T (1997). The cellular and molecular basis of peripheral nerve regeneration. *Molecular Neurobiology* 14: 67–116.
- Georges PC, Miller WJ, Meaney DF, Sawyer ES, and Janney PA (2006). Matrices with compliance comparable to that of brain tissue select neuronal over glial growth in mixed cortical cultures. *Biophysical Journal* 90: 3012–3018.
- Gibson RM, Craig SE, Heenan L, Tournier C, and Humphries MJ (2005). Activation of integrin alpha5beta1 delays apoptosis of Ntera2 neuronal cells. *Molecular and Cellular Neuroscience* 28: 588–598.
- Gomes ED, Mendes SS, Leite-Almeida H, et al. (2016). Combination of a peptide-modified gellan gum hydrogel with cell therapy in a lumbar spinal cord injury animal model. *Biomaterials* 105: 38–51.
- Gooch CL, Pracht E, and Borenstein AR (2017). The burden of neurological disease in the United States: A summary report and call to action. *Annals of Neurology* 81: 479–484.
- Rask CA (1991). Biological actions of nerve growth factor in the peripheral nervous system. *Eur Neurol*. 41 (Suppl 1):14-19.
- Thoenen H. (2000). Neurotrophins and activity-dependent plasticity. *Prog Brain Res*. 128:183-191.
- Costales J, Kolevzon A. (2016). The therapeutic potential of insulin-like growth factor-1 in central nervous system disorders. *Neurosci Biobehav Rev*. 63:207-222.
- Keskin I, Kaplan S, Kalkan S, Sutcu M, Ulkay MB, Esener OB. (2015). Evaluation of neuroprotection by melatonin against adverse effects of prenatal exposure to a nonsteroidal anti-inflammatory drug during peripheral nerve development. *Int J Dev Neurosci*. 41:1-7.
- Geuna S, Raimondo S, Fregnan F, Haastert-Talini K, Grothe C. (2016). *In vitro* models for peripheral nerve regeneration. *Eur J Neurosci*. 43:287-296.
- Geuna S. (2015). The sciatic nerve injury model in pre-clinical research. *J Neurosci Methods*. 243:39-46.
- Turgut M, Kaplan S. (2011). Effects of melatonin on peripheral nerve regeneration. *Recent Pat Endocr Metab Immune Drug Discov*. 5:100-108.
- Boyd JG, Gordon T. (2003). Neurotrophic factors and their receptors in axonal regeneration and functional recovery after peripheral nerve injury. *Mol Neurobiol*. 27:277-324.
- Sebben AD, Lichtenfels M, da Silva JLB. (2011). Peripheral nerve regeneration: Cell therapy and

- neurotrophic factors. *Revista Brasileira de Ortopedia (English Edition)*. 46:643-649.
24. Barde YA, Edgar D, Thoenen H. (1982). Purification of a new neurotrophic factor from mammalian brain. *EMBO J*. 1:549-553.
 25. Yan H, Zhang F, Chen MB, Lineaweaver WC (2009). Chapter 10: Conduit luminal additives for peripheral nerve repair. *Int Rev Neurobiol*. 87:199-225.
 26. Yano H, Chao MV. (2000). Neurotrophin receptor structure and interactions. *Pharm Acta Helv*. 74:253-260.
 27. Barbacid M. (1994). The Trk family of neurotrophin receptors. *J Neurobiol*. 25:1386-1403.
 28. Schneider R, Schweiger M. (1991). A novel modular mosaic of cell adhesion motifs in the extracellular domains of the neurogenic trk and trkB tyrosine kinase receptors. *Oncogene*. 6:1807-1811.
 29. Saarma M, Sariola H. (1999). Other neurotrophic factors: glial cell line-derived neurotrophic factor (GDNF). *Microsc Res Tech*. 45:292-302.
 30. Henderson CE, Phillips HS, Pollock RA. (1994). GDNF: A potent survival factor for motoneurons present in peripheral nerve and muscle. *Science*. 266:1062-1064.
 31. Patel M, Mao L, Wu B, VandeVord P. (2009). GDNF blended chitosan nerve guides: An *in vivo* study. *J Biomed Mater Res A*. 90:154-165.
 32. Heinrich PC, Behrmann I, Muller-Newen G, Schaper F, Graeve L. (1998). Interleukin-6-type cytokine signalling through the gp130/Jak/STAT pathway. *Biochem J*. 334:297-314.
 33. Yang P, Wen H, Ou S, Cui J, Fan D. (2012). IL-6 promotes regeneration and functional recovery after cortical spinal tract injury by reactivating intrinsic growth program of neurons and enhancing synapse formation. *Exp Neurol*. 236:19-27.
 34. Stolp HB. (2013). Neurotrophic cytokines in normal brain development and neurodevelopmental disorders. *Mol Cell Neurosci*. 53:63-68.
 35. Harvey AR, Lovett SJ, Majda BT, et al. (2015). Neurotrophic factors for spinal cord repair: Which, where, how and when to apply, and for what period of time? *Brain Res*. 1619:36-71.
 36. Zurn AD, Winkel L, Menoud A, Djabali K, Aebischer P. (1996). Combined effects of GDNF, BDNF, and CNTF on motoneuron differentiation *in vitro*. *J Neurosci Res*. 44:133-141.
 37. Priestley JV, Ramer MS, King VR, McMahon SB, Brown RA. (2002). Stimulating regeneration in the damaged spinal cord. *J Physiol Paris*. 96:123-133.
 38. Hoyng SA, De Winter F, Gnani S, et al. (2014). Comparative morphological, electrophysiological and functional analysis of axon regeneration through peripheral nerve autografts genetically modified to overexpress BDNF, CNTF, GDNF, NGF, NT3 or VEGF. *Exp Neurol*. 261:578-593.
 39. Kobayashi NR, Bedard AM, Hincke MT, Tetzlaff W. (1996). Increased expression of BDNF and trkB mRNA in rat facial motoneurons after axotomy. *Eur J Neurosci*. 8:1018-1029.
 40. Vögelin E, Baker JM, Gates J, Dixit V, Constantinescu MA, Jones NF (2006). Effects of local continuous release of brain derived neurotrophic factor (BDNF) on peripheral nerve regeneration in a rat model. *Exp Neurol*. 199:348-353.
 41. Tchetchelnitski V, van den Eijnden M, Schmidt F, Stoker AW (2014). Developmental co-expression and functional redundancy of tyrosine phosphatases with neurotrophin receptors in developing sensory neurons. *Int J Dev Neurosci*. 34:48-59.
 42. Gibbons AS, Bailey KA. (2005). BDNF and NT-3 regulation of trkB and trkC mRNA levels in the developing chick spinal cord. *Neurosci Lett*. 385:41-45.
 43. Kaplan S, Odaci E, Unal B, Sahin B, Fornaro M. (2009). Chapter 2: Development of the peripheral nerve. *Int Rev Neurobiol*. 87:9-26.
 44. Onger ME, Türkmen AP, Elibol E. (2015). Chapter 3 – Embryology of the peripheral nerves A2 – Nerves and nerve injuries. Academic Press, San Diego, USA pp. 37-40.
 45. Türkmen AP, Altunkaynak BZ, Onger ME (2015). Chapter 4 – Development of the cranial nerves A2 – Nerves and nerve injuries. Academic Press, San Diego, USA. pp. 41-53.
 46. Funakoshi H, Frisén J, Barbany G, Timmusk T, Zachrisson O, Verge VM, Persson H. (1993). Differential expression of mRNAs for neurotrophins and their receptors after axotomy of the sciatic nerve. *J Cell Biol*. 123:455-465.
 47. Naveilhan P, ElShamy WM, Ernfors P. (1997). Differential regulation of mRNAs for GDNF and its receptors Ret and GDNFR alpha after sciatic nerve lesion in the mouse. *Eur J Neurosci*. 9:1450-1460.
 48. Allen SJ, Watson JJ, Shoemark DK, Barua NU, Patel NK. (2013). GDNF, NGF and BDNF as therapeutic options for neurodegeneration. *Pharmacol Ther*. 138:155-175.
 49. Åberg, M., Ljungberg, C., Edin, E., Millqvist, H., Nordh, E., Theorin, A. (2009). Clinical evaluation of a resorbable wrap-around implant as an alternative to nerve repair: a prospective, assessor-blinded, randomized clinical study of sensory, motor and functional recovery after peripheral nerve repair. *J. Plast. Reconstr. Aesthetic Surg*. 62, 1503–1509. doi: 10.1016/j.bjps.2008.06.041
 50. Ahmed, Z., Underwood, S., and Brown, R. A. (2003). Nerve guide material made from fibronectin: assessment of *in vitro* properties. *Tissue Eng*. 9, 219–231. doi: 10.1089/107632703764664693
 51. Aigner, T. B., Haynl, C., Salehi, S., O'Connor, A., and Scheibel, T. (2020). Nerve guidance conduit design based on self-rolling tubes. *Mater. Today Biol*. 5:100042. doi: 10.1016/j.mtbio.2020.100042
 52. Albala, D. M., and Lawson, J. H. (2006). Recent clinical and investigational applications of fibrin sealant in selected surgical specialties. *J. Am. Coll. Surg*. 202, 685–697. doi: 10.1016/j.jamcollsurg.2005.11.027
 53. Alberti, K. A., Hopkins, A. M., Tang-Schomer, et al. (2014). The behavior of neuronal cells on tendon-derived collagen sheets as potential substrates for nerve regeneration. *Biomaterials* 35, 3551–3557. doi: 10.1016/j.biomaterials.2013.12.082
 54. Alessandrino, A., Fregnan, F., Biagiotti, M., Muratori, L., Bassani, G. A., Ronchi, G. (2019). SilkBridgeTM: a novel biomimetic and biocompatible silk-based nerve conduit. *Biomater. Sci*. 7, 4112–4130. doi: 10.1039/c9bm00783k
 55. Pfister, L. A., Alther, E., Papaloizos, M., et al. (2008). Controlled nerve growth factor release from multi-ply alginate/chitosan-based nerve conduits. *Eur. J. Pharm. Biopharm*. 69, 563–572. doi: 10.1016/j.ejpb.2008.
 56. Altman, G. H., Diaz, F., Jakuba, C., Calabro, T., Horan, R. L., Chen, J. (2003). Silk-based biomaterials. *Biomaterials* 24, 401–416. doi: 10.1016/S0142-9612(02)00353-8
 57. Angius, D., Wang, H., Spinner, R. J., Gutierrez-Cotto, Y., Yaszemski, M. J., and Windebank, A. J. (2012). A systematic review of animal models used to study nerve regeneration in tissue-engineered scaffolds. *Biomaterials* 33, 8034–8039. doi: 10.1016/j.biomaterials.2012.07.056
 58. Anjum, A., Zuber, M., Zia, K. M., Noreen, A., Anjum, M. N., and Tabasum, S. (2016). Microbial production of polyhydroxyalkanoates (PHAs) and its copolymers: a review of recent advancements. *Int. J. Biol. Macromol*. 89, 161–174. doi: 10.1016/j.ijbiomac.2016.04.069
 59. Cao, Y., and Wang, B. (2009). Biodegradation of silk biomaterials. *Int. J. Mol. Sci*. 10, 1514–1524. doi: 10.3390/ijms10041514
 60. Carvalho, C. R., Oliveira, J. M., and Reis, R. L. (2019). Modern trends for peripheral nerve repair and regeneration: beyond the hollow nerve guidance conduit. *Front. Bioeng. Biotechnol*. 7:337. doi: 10.3389/fbioe.2019.00337
 61. Cenni, E., Ciapetti, G., Stea, S., Corradini, A., and Carozzi, F. (2000). Biocompatibility and performance *in*

- vitro* of a hemostatic gelatin sponge. J. Biomater. Sci. Polym. Ed. 11, 685–699. doi: 10.1163/156856200743959
62. Chang, J.-Y., Ho, T.-Y., Lee, H.-C., Lai, Y.-L., Lu, M.-C., Yao, C.-H. (2009). Highly permeable genipin-cross-linked gelatin conduits enhance peripheral nerve regeneration. *Artif. Org.* 33, 1075–1085. doi: 10.1111/j.1525-1594.2009.00818.
 63. Chen, G.Q. (2010). “Plastics Completely Synthesized by Bacteria: Polyhydroxyalkanoates,” in: Berlin: Springer, 17–37. doi: 10.1007/978-3-642-03287-5_2
 64. Chen, H., Xie, S., Yang, Y., Zhang, J., and Zhang, Z. (2018). Multiscale regeneration scaffold *in vitro* and *in vivo*. *J. Biomed. Mater. Res. Part B Appl. Biomater.* 106, 1218-1225. doi: 10.1002/jbm.b.33926
 65. Chen, P. R., Chen, M. H., Lin, F. H., and Su, W. Y. (2005). Release characteristics and bioactivity of gelatin-tricalcium phosphate membranes covalently immobilized with nerve growth factors. *Biomaterials* 26, 6579–6587. doi: 10.1016/j.biomaterials.2005.03.037
 66. Chen, S., Zhao, Y., Yan, X., Zhang, L., Li, G., and Yang, Y. (2019). PAM/GO/gel/SA composite hydrogel conduit with bioactivity for repairing peripheral nerve injury. *J. Biomed. Mater. Res. Part A.* 107, 1273-1283. doi: 10.1002/jbm.a.36637
 67. Chen, Y. S., Chang, J. Y., Cheng, C. Y., Tsai, F. J., Yao, C. H., and Liu, B. S. (2005). An *in vivo* evaluation of a biodegradable genipin-cross-linked gelatin peripheral nerve guide conduit material. *Biomaterials* 26, 3911–3918. doi: 10.1016/j.biomaterials.2004.09.060
 68. Chiono, V., and Tonda-Turo, C. (2015). Trends in the design of nerve guidance channels in peripheral nerve tissue engineering. *Prog. Neurobiol.* 131, 87–104. doi: 10.1016/j.pneurobio.2015.06.001
 69. Chrz, aszcz, P., Derbisz, K., Suszyński, K., et al., (2018). Application of peripheral nerve conduits in clinical practice: a literature review. *Neurol. Neurochir. Pol.* 52, 427–435. doi: 10.1016/j.pjnns.2018.06.003
 70. Clements, B. A., Bushman, J., Murthy, N. S., Ezra, M., Pastore, C. M., and Kohn, J. (2016). Design of barrier coatings on kink-resistant peripheral nerve conduits. *J. Tissue Eng.* 7, 2041731416629471. doi: 10.1177/2041731416629471
 71. Costantini, M., Colosi, C., Mozetic, P., Jaroszewicz, J., Tosato, A., Rainer, A. (2016). Correlation between porous texture and cell seeding efficiency of gas foaming and microfluidic foaming scaffolds. *Mater. Sci. Eng. C* 62, 668-677. doi: 10.1016/j.msec.2016.02.010
 72. Crosio, A., Fornasari, B., Gambarotta, G., et al. (2019). Chitosan tubes enriched with fresh skeletal muscle fibers for delayed repair of peripheral nerve defects. *Neural Regen. Res.* 14:1079. doi:10.4103/1673-5374.250628
 73. Dadsetan, M., Knight, A. M., Lu, L., Windebank, A. J., and Yaszemski, M. J. (2009). Stimulation of neurite outgrowth using positively charged hydrogels. *Biomaterials* 30, 3874–3881. doi: 10.1016/j.biomaterials.2009.04.018
 74. Saltzman, E. B., Villa, J. C., Doty, S. B., Feinberg, J. H., Lee, S. K., and Wolfe, S. W. (2019). A comparison between two collagen nerve conduits and nerve autograft: a rat model of motor nerve regeneration. *J. Hand Surg. Am.* 44, 700.e1–700.e9. doi: 10.1016/j.jhsa.2018.
 75. Chen, P. R., Chen, M. H., Lin, F. H., and Su, W. Y. (2005). Release characteristics and bioactivity of gelatin-tricalcium phosphate membranes covalently immobilized with nerve growth factors. *Biomaterials* 26, 6579–6587. doi: 10.1016/j.biomaterials.2005.03.037
 76. Chen, S., Zhao, Y., Yan, X., Zhang, L., Li, G., and Yang, Y. (2019). PAM/GO/gel/SA Composite hydrogel conduit with bioactivity for repairing peripheral nerve injury. *J. Biomed. Mater. Res. Part A.* 107, 1273-1283. doi: 10.1002/jbm.a.36637.
 77. Liu, Y., and Hsu, S. (2020). Biomaterials and neural regeneration. *Neural Regen. Res.* 15:1243. doi: 10.4103/1673-5374.272573
 78. Loverde, J. R., Ozoka, V. C., Aquino, R., Lin, L., and Pfister, B. J. (2011). Live imaging of axon stretch growth in embryonic and adult neurons. *J. Neurotr.* 28, 2389-2403. doi: 10.1089/neu.2010.1598
 79. Loverde, J. R., and Pfister, B. J. (2015). Developmental axon stretch stimulates neuron growth while maintaining normal electrical activity, intracellular calcium flux, and somatic morphology. *Front. Cell. Neurosci.* 9:308. doi: 10.3389/fncel.2015.00308
 80. Lundborg, G. (2000). A 25-year perspective of peripheral nerve surgery: evolving neuroscientific concepts and clinical significance. *J. Hand Surg. Am.* 25, 391–414. doi: 10.1053/jhsu.2000.4165
 81. Lyons, K. M., Pelton, R. W., and Hogan, B. L. M. (1990). Organogenesis and pattern formation in the mouse: RNA distribution patterns suggest a role for bone morphogenetic protein-2A (BMP-2A). *Development* 109, 833-844. doi:10.1016/0168-9525(90)90274-a
 82. Magaz, A., Faroni, A., Gough, J. E., Reid, A. J., Li, X., and Blaker, J. J. (2018). Bioactive silk-based nerve guidance conduits for augmenting peripheral nerve repair. *Adv. Healthc. Mater.* 7:e1800308. doi: 10.1002/adhm.201800308
 83. Maiti, B., and Díaz, D. D. (2018). 3D printed polymeric hydrogels for nerve regeneration. *Polymers* 10:1041. doi: 10.3390/POLYM10091041
 84. Marshall, S. J., Bayne, S. C., Baier, R., Tomsia, A. P., and Marshall, G. W. (2010). A review of adhesion science. *Dent. Mater.* 26, e11–e16. doi: 10.1016/j.dental.2009.11.157
 85. Kalbermatten, D. F., Erba, P., Mahay, D., Wiberg, M., Pierer, G., and Terenghi, G. (2008a). Schwann cell strip for peripheral nerve repair. *J. Hand Surg. Eur.* 33, 587–594. doi: 10.1177/1753193408090755.
 86. Kaplan, H. M., Mishra, P., and Kohn, J. (2015). The overwhelming use of rat models in nerve regeneration research may compromise designs of nerve guidance conduits for humans. *J. Mater. Sci. Mater. Med.* 26, 1–5. doi: 10.1007/s10856-015-5558-4
 87. Karimi, A., Karbasi, S., Razavi, S., and Zargar, E. N. (2018). Poly(hydroxybutyrate)/chitosan Aligned Electrospun Scaffold as a Novel Substrate for Nerve Tissue Engineering. *Adv. Biomed. Res.* 7:44. doi: 10.4103/abr.abr_277_16
 88. Gupta, P., and Nayak, K. K. (2016). Optimization of keratin/alginate scaffold using RSM and its characterization for tissue engineering. *Int. J. Biol. Macromol.* 85, 141–149. doi: 10.1016/j.ijbiomac.2015.12.010.